”In Q2 2024, the rate of new patient starts was 12% higher than the previous quarter and the rate ofdiscontinuations was 46% lower than in the previous quarter. The number of patients on active therapyincreased to 900 at 1 August 2024. The rate of persistence on therapy continues to trend more than10% higher than the experience in clinical trials, with the current rate after 9 months of treatment at58%. Penetration continues to increase, with approximately 30% of the 5,000 diagnosed patients havinginitiated therapy. In market research, physicians surveyed stated that over the next 24 months theyexpect to expand prescribing to more than 70% of their eligible patients.”
Considering the shellacking the share price has received after “drop-out” , not too shabby looking ahead .
NEU Price at posting:
$15.59 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)